← Open Payments lookup

NPI 1891825733: Open Payments

NPI 1891825733. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$795 in 52 payments from 16 companies in 2025. Trend: 2023 $995 · 2024 $1,060 · 2025 $795

Food & beverage: $795
CompanyPaymentsAmount
Amgen Inc.13$175
ABBVIE INC.13$141
Novartis Pharmaceuticals Corporation5$86
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)4$83
Verona Pharma, Inc.3$55
Astellas Pharma US Inc2$48
E.R. Squibb & Sons, L.L.C.2$41
Axsome Therapeutics, Inc.2$38
Actelion Pharmaceuticals US, Inc.1$20
PFIZER INC.1$18

Products named: VRAYLAR, EVENITY, LEQVIO, CAPLYTA, OTEZLA, Ohtuvayre, Veozah, Auvelity.